Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Wendel-Hansen, C. Lundberg, H. Lindberg, B. Sparf, S. Persson, N. Rydell, A. Perolari, M. Persson, A. Jansson, E. Landström, M. Fant, L. Larsson (Uppsala, Sweden). A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study. Eur Respir J 2007; 30: Suppl. 51, 3649

Member's Comments

No comment yet.

Related content which might interest you: Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Preclinical development of an IL-13 neutralising antibody, CAT-354, for the treatment of human asthma Source: Eur Respir J 2005; 26: Suppl. 49, 367s Year: 2005 MEMP1972A, an anti-M1 prime monoclonal antibody, reduces serum IgE in healthy and allergic rhinitis subjects Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Phase 2, mutlicenter, double-blind study of CNTO 148, a human monoclonal anti-TNF α antibody, in symptomatic patients with severe persistent asthma Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007 Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma Source: Eur Respir J 2001; 18: 45-52 Year: 2001 Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma? Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD Year: 2019 The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001 Tolerability assessment of a recombinant humanized monoclonal anti-IgE antibody (omalizumab) as a treatment for seasonal allergic rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 116s Year: 2002 A multiple ascending subcutaneous (SC) dose study of MEDI-563, a humanized anti-IL-5Rα monoclonal antibody, in adult asthmatics Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Safety profile and clinical activity of multiple subcutaneous (SC) doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in subjects with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010 PK/PD, safety and tolerability of a human anti-IL-1B monoclonal antibody (ACZ885) in healthy subjects Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006 Novel inhaled delivery of anti-IL-13 mAb (Fab fragment): preclinical efficacy in allergic asthma Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007 Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Population pharmacokinetics of tralokinumab, an investigational anti-IL-13 monoclonal antibody, in asthmatic and healthy adults Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions Source: Eur Respir J 2003; 21: 799-803 Year: 2003 Patient characteristics that can predict response to omalizumab an (anti-IgE antibody) for achieving better control of asthmatic patients Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019